Amarin shares are trading higher. The company announced it received a Decision to Grant from the European Patent Office for a new patent covering VAZKEPA that will extend VAZKEPA exclusivity eight additional years into 2039.
Portfolio Pulse from Benzinga Newsdesk
Amarin Corporation's stock is trading higher following the announcement that the European Patent Office has granted a new patent for VAZKEPA, extending its exclusivity by eight years until 2039.
April 03, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amarin's new patent for VAZKEPA in Europe extends its market exclusivity until 2039, potentially enhancing its long-term revenue prospects.
The extension of VAZKEPA's exclusivity period until 2039 due to the new patent grant is a significant positive development for Amarin. It not only secures its market position in Europe for a longer period but also potentially enhances its revenue generation capabilities from this product. This development is likely to be viewed positively by investors, leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100